Jump to content

A Digital Platform to Automate Production, Optimization, and Evaluation of Viral and Non-Viral Vectors for Cell and Gene Therapies

Advanced Therapies, London
March 19, 2024

Cell and gene therapies (CGT) require efficient, on-target gene delivery to maximize clinical efficacy and safety. Gene delivery systems can include viral vectors such as recombinant adeno-associated virus (AAV), lentivirus (LV) and novel technologies such as antibody-targeted lipid nanoparticles (LNPs).

This poster explains how Genedata Biologics® provides a robust digital platform for developing CGTs using targeted gene delivery systems. The poster details the high-throughput tools to optimize delivery of therapeutic payloads with novel viral and non-viral vectors. It also details the powerful functionalities for overseeing, controlling, and evaluating all associated production processes conducted within the laboratory to increase process efficiency and allow end-to-end data capture.

By streamlining data management, the Genedata Biologics platform enables systematic optimization of gene delivery systems. Researchers can efficiently identify and evaluate promising CGT candidates, expediting the path toward effective therapies.

Request Resource

By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Genedata privacy policy